All News
Which patients with psoriasis are at risk to develop PsA?
The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.
Read Article
EULAR 2021 – Day 4 Report
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Read Article
Artificial intelligence brings clarity to early bony changes in inflammatory arthritis
Subtle early bony changes in inflammatory arthritis can be hard even for experienced rheumatologists to interpret, even though they have traditionally been considered to become disease-defining as they progress.
Read Article
Psoriatic arthritis mortality & morbidities
Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing psoriasis patients with or without PsA.
Read Article
RheumNow Podcast - Best of EULAR 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read Article
Q-DAPSA for Measuring Disease Activity in PsA
Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.
Read Article
EULAR 2021 - Day 3 Report
Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
Read Article
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
